THE RATE OF METABOLIC SYNDROME AND COMORBIDITIES IN PATIENTS WITH GOUT: DATA OF A MULTICENTER TRIAL

Objective: to study the rate of metabolic syndrome (MS) and its components among gout patients in different regions of the Russian Federation. Subjects and methods. This cross-sectional multicenter study enrolled 2277 gout patients, including 1963 (86.2%) men and 314 (13.8%) women, from 12 independent medical centers in different regions of the Russian Federation. The patients over 18 years of age who met the classification criteria for gout, elaborated by S. Wallace et al., were included. The diagnosis of MS was established on the basis of Adult Treatment Panel III (ATP III) criteria. The presence of MS, its individual components and comorbidities were recorded. Results. The total rate of MS in the patients with gout was 57%; however, it varied substantially (from 15 to 77%) in different centers. Among the comorbidities, arterial hypertension was most common (in three fourths of the patients), coronary heart disease (CHD) and type 2 diabetes mellitus were less common (43 and 25%, respectively); 15% of the patients had sustained myocardial infarction, renal and cardiac failure was also observed in 15%. In the gout patients, MS was associated with the presence of CHD. Conclusion. The patients with gout were observed to have a high rate of MS (57%), its components, and cardiovascular diseases. The findings suggest that there is a relationship between the presence of MS and the development of CHD.

goat, metabolic syndrome, cardiovascular diseases, multicenter trial

1. <div><p>Насонова В.А., Барскова В.Г. Ранние диагностика и лечение подагры — научно обоснованное требование улучшения трудового и жизненного прогноза больных. Науч.-практич. ревматол. 2004; 1: 5-7.</p><p>Emmerson B. Hyperlipidemia, in hyperuricaemia and gout. Ann Rheum Dis 1998; 57: 509-10.</p><p>Mikuls T.R., Farrar J.T., Bilker W.B. et al. Gout epidemiology: results from the UK General Practice Research Database 1990-1999. Ann Rheum Dis 2005; 64: 267-72.</p><p>Choi H.K., de Vera M.A., Krishnan E. Gout and the risk of type 2 diabetes among men with a high cardiovascular risk profile. Rheumatology 2008; 47: 1567-70.</p><p>Елисеев М.С. Метаболические нарушения у больных подагрой. Доктор.ру 2009; 3: 67-71.</p><p>Marwah R.K. Comorbidities in gouty arthritis. J Investig Med 2011; 59(8): 1211 —20.</p><p>Ford E.S., Giles W.H., Dietz W.H. Prevalence of the metabolic syndrome among US adults: findings from the third National Health and Nutrition Examination Survey. JAMA 2002; 287(3): 356—9.</p><p>Choi H.K., Ford E.S., Li C., Curhan G. Prevalence of the metabolic syndrome in patients with gout: the Third National Health and Nutrition Examination Survey. Arthr Rheum (Arthr Care Res) 2007; 57(1): 109—15.</p><p>Wallace S.L., Robinson H., Masi A.T. et al. Preliminary criteria for the classification of the acute arthritis of gout. Arthr Rheum 1977; 20: 895-900.</p><p>Executive summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 2001; 285(19): 2486—97.</p><p>Alberti K.G., Zimmet P.Z. for the WHO Consultation. Definition, diagnosis and classification of diabetes mellitus and its complications. Part I: diagnosis and classification of diabetes mellitus: provisional report of a WHO consultation. Diabet Med 1998; 15: 539-53.</p><p>Chobanian A.V., Bakris G.L., Black H.R. et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: The JNC 7 Report. JAMA 2003; 289(19): 2560—71.</p><p>Feldman E.B., Wallace S.L. Hypertriglyceridemia in gout. Circulation 1964; 29: 508-13.</p><p>Berkowitz D. Gout, hyperlipidemia and diabetes interrelationships. JAMA 1966; 197: 77-80.</p><p>Van den Bussche H. Which chronic diseases and disease combinations are specific to multimorbidity in the elderly? Results of a claims data based cross-sectional study in Germany. BMC Public Health 2011; 11: 101.</p><p>Yoo H.-G., Lee S.-I., Chae H.-J. Prevalence of insulin resistance and metabolic syndrome in patients with gouty arthritis. Rheumatol Int 2011; 31(4): 485—91.</p><p>Rho Y.H., Choi S.J., Lee Y.H. et al. The Prevalence of Metabolic Syndrome in Patients with Gout: A Multicenter Study. J Korean Med Sci 2005; 20: 1029-33.</p><p>Vazguez-Mellado J., Garsia C.G., Vazguez S.G. et al. Metabolic syndrome and ischemic heart disease in gout. J Clin Rheumatol 2004; 10(3): 105—9.</p><p>Елисеев М.С., Барскова В.Г. Метаболический синдром при подагре. Вестн. РАМН 2008; 6: 29-32.</p><p>Puig J.G., Martinez M.A. Hyperuricemia, gout and the metabolic syndrome. Curr Opin Rheumatol 2008; 20: 187-91.</p><p>Annemans L., Spaepen E., Gaskin M. Gout in the UK and Germany: prevalence, comorbidities and management in general practice 2000—2005. Ann Rheum Dis 2008; 67: 960-6.</p><p>Насонова В.А., Елисеев М.С., Барскова В.Г. Влияние возраста на частоту и выраженность признаков метаболического синдрома у больных подагрой. Совр. ревматол. 2007; 1: 31-6.</p><p>Lottman K., Chen X., Schädlich P.K. Association between gout and all-cause as well as cardiovascular mortality: a systematic reviw. Curr Rheumatol Rep 2012; 14: 195-203.</p><p>Денисов И.С., Елисеев М.С., Барскова В.Г. Анализ выживаемости, случаев смерти больных подагрой. Тезисы. Владимир (в печати).</p><p>Елисеев М.С., Барскова В.Г., Насонова В.А. Клиническое значение метаболического синдрома при подагре. Клин. геронтол. 2006; 2: 29-33.</p><p>Primatesta P., Plana E., Rothenbacher D. Gout treatment and comorbidities: a retrospective cohort study in a large US managed care population. BMC Musculoskelet Disord 2011; 12: 103.</p><p>Барскова В.Г., Елисеев М.С., Кудаева Ф.М. и др. Влияние метформина на течение подагры и инсулинорезистентность. Клин. мед. 2009; 7: 41-6.</p></div><br />